2006 - 2010

2010

• Modified vaccinia virus Ankara (MVA) based vaccines-immunostimulatory and protective capacity.
  Lehmann M.H., Kremer M., Suezer Y., Sutter G.
  In: Biomedical and Life Sciences. The Challenge of Highly Pathogenic Microorganisms. Springer Verlag (2010)
• Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. (online-abstract)
  Kreijtz J., Suezer Y., Bodewes R., Schwantes A., van Amerong G., Verburgh J. R., de Mutsert G., van den Brand J., van Trierum E.St., Kuiken T., Fouchier M.A.R., Osterhaus A., Sutter G., Rimmelzwaan G.
  J. Gen. Virol., 91, 2745-2752 (2010)
• Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion. (online-abstract)
  Frenz T., Waibler Z., Hofmann J., Hamdorf M., Lantermann M., Reizis B., Tovey G.M., Aichele P., Sutter G., Kalinke U.
  Eur. J. Immunol., 40, 2769-2777 (2010)
• Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells. (online-abstract)
  Zwilling J., Sliva K., Schwantes A., Schnierle B., Sutter G.
  Virology, 404, 231-239 (2010)
• Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. (online-abstract)
  Moutaftsi M., Tscharke C.D., Vaughan K., Koelle M.D., Stern L., Calvo-Calle M., Ennis F., Terajima M., Sutter G., Crotty S., Drexler I., Franchini G., Yewdell W.J., Head R.S., Blum J., Peters B., Sette A.
  Future Microbiol., 5, 221-239 (2010)
• Viral host range factors C7 or K1 are essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit PKR-mediated elF2-a phosphorylation. (pdf, 700 KB)
  Backes S., Sperling K., Zwilling J., Gasteiger G., Ludwig H., Kremmer E., Schwantes A., Staib C., Sutter G.
  J. Gen. Virol., 91, 470-482 (2010)

2009

• Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. (pdf, 7,3 MB)
  Halle St., Dujardin C.H., Bakocevic N., Fleige H., Danzer H., Willenzon St., Suezer Y., Hämmerling G., Garbi N., Sutter G., Worbs T., Förster R.
  J. Exp. Med., 12, 2593-2601(2009)
• Smallpox vaccines – new formulations and revised strategies for vaccination. (pdf, 710 KB)
  Paran N., Sutter G.
  Hum. Vaccines, 5(12), 824-831 (2009)
• MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. (pdf, 900 KB)
  Kreijtz J., Suezer Y., de Mutsert G., van Amerongen G., Schwantes A., Fouchier R., Löwer J., Osterhaus A., Sutter G., Rimmelzwaan G.
  PLoS ONE, e7790 (2009)
• Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. (online-abstract)
  Kreijtz J., Suezer Y., de Mutsert G., van den Brand J., van Amerongen G., Schnierle B.S., Kuiken T., Fouchier R., Löwer J., Osterhaus A., Sutter G., Rimmelzwaan G.
  Vaccine, 27, 6296-6299 (2009)
• The orthopoxvirus 68k ankyrin-like protein is essential for DNA replication and complete gene expression of modified vaccinia virus Ankara in non-permissive human and murine cells. (pdf, 1,3 MB)
  Sperling K.M., Schwantes A., Staib C., Schnierle B.S., Sutter G.
  J. Virol., 83, 6029-6038 (2009)
• Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. (online-abstract)
  Rimmelzwaan G., Sutter G.
  Expert Rev. Vaccines, 8, 447-454 (2009)
• An IFN-y-induced IRF-1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts. (pdf, 1,7 MB)
  Trilling M., Le V.T.K., Zimmermann A., Ludwig H., Pfeffer K., Sutter G., Smith G.L., Hengel H.
  J. Virol., 83, 3684-3695 (2009)
• Modified vaccinia virus Ankara (MVA) triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. (pdf, 3,2 MB)
  Lehmann M.H., Kastenmüller W., Kademir J.D., Brandt F., Suezer Y., Sutter G.
  J. Virol., 83, 2540-2552 (2009)
• Marker gene swapping facilitates recombinant modified vaccinia Ankara production by host-range selection. (online-abstract)
  Di Lullo G., Soprana E., Panigada M., Palini A., Erfle V., Staib C., Sutter G., Siccardi A.G.
  J. Virol. Methods, 156, 37-43 (2009)
• Recombinant modified vacccinia Ankara expressing the hemaglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. (pdf, 600 KB)
  Kreijtz J., Suezer Y., de Mutsert G., van den Brand J.M., van Amerongen G., Schnierle B.S., Kuiken T., Fouchier R.A., Löwer J., Osterhaus A.D., Sutter G., Rimmelzwaan G.F.
  J. Infect. Dis., 199, 405-413 (2009)
• Vaccinia virus-mediated inhibition of type I interferon responses is a mult-factorial process involvig the soluble type I interferon receptor B18 and intracellular components. (pdf, 550 KB)
  Waibler Z., Anzaghe M., Frenz T., Schwantes A., Pöhlmann C., Ludwig H., Palomo-Otero M., Alcami A., Sutter G., Kalinke U.
  J. Virol., 83, 1563-1571 (2009)
• Postexposure immunization with vaccinia virus MVA or conventional Lister vaccine provides solid protection in murine model for human smallpox. (pdf, 570 KB)
  Paran N., Suezer Y., Lustig S., Israely T., Schwantes A., Melamed S., Katz L., Preuß T., Hanschmann K., Kalinke U., Erez N., Levin R., Velan B., Löwer J., Shafferman A., Sutter G.
  J. Infect. Dis., 199(1), 39-48 (2009)

nach oben2008

• Evaluation of vaccination strategies against infection with feline immunodeficiency virus based on recombinant viral vectors expressing Rev and OrfA. (online-abstract)
  Huisman W., Schrauwen E., Tijhaar E., Suezer Y., Pas S., van Amerongen G., Sutter G., Rimmelzwaan G., Osterhaus A.
  Vet. Immunol. Immunopathol., 126, 332-338 (2008)
• In vivo attenuation of recombinant murine gammaherpesvirus 68 is due to the expression and immunogenicity but not the insertion of foreign sequences. (online-abstract)
  EI-Gogo S., Flach B., Staib C., Sutter G., Adler H.
  Virology, 380, 322-327 (2008)
• Vaccination with a modified vaccinia virus Ankara-based vaccine protects mice from allergic sensitization. (online-abstract)
  Albrecht M., Suezer Y., Staib C., Sutter G., Vieths S., Reese G.
  J. Gene Med., 10, 1324-1333 (2008)
• The highly conserved orthopoxvirus 68k ankyrin-like protein i spart of a cellular SCF ubiquitin ligase complex. (online-abstract)
  Sperling K., Schwantes A., Schnierle B.S., Sutter G.
  Virology, 374, 234-239 (2008)
• Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions.(online-abstract)
  Veits J., Römer-Oberdörfer A., Helferich D., Durban M., Suezer Y., Sutter G., Mettenleiter T.C.
  Vaccine, 26, 1688-1696 (2008)
• Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model. (online-abstract)
  El-Gogo S., Staib C., Lasarte J.J., Sutter G., Adler H.
  J. Gene Med., 10, 177-186 (2008)

nach oben2007

• Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. (pdf, 230 KB)
  Waibler Z., Anzaghe M., Ludwig H., Akira S., Weiss S., Sutter G., Kalinke U.
  J. Virol., 81, 12102-12110 (2007)
• Crosspriming of cytotoxic T-cells dictates antigen requisites for MVA vector vaccines. (pdf, 550 KB)
  Gasteiger G., Kastenmüller W., Ljapoci R., Sutter G., Drexler I.
  J. Virol., 81(21), 11925-11936 (2007)
• Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge. (online-abstract)
  Antonis A.F., van der Most R.G., Suezer Y., Stockhofe-Zurwieden N., Daus F., Sutter G., Schrijver R.S.
  Vaccine, 25, 4818-4827 (2007)
• Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induced a type I IFN receptor-dependent switch to neutralizing lgG antibodies. (pdf, 780 KB)
  Bach P., Kamphuis E., Odermatt B., Sutter G., Buchholz C.J., Kalinke U.
  J. Immunol., 178, 5839-5847 (2007)
• Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model. (online-abstract)
  El-Gogo S., Staib C., Meyr M., Erfle V., Sutter G., Adler H.
  Vaccine, 25, 3934-3945 (2007)
• Vaccinia virus double-stranded RNA-binding protein E3 does not interfere with siRNA-mediated gene silencing in mammalian cells. (online-abstract)
  Lantermann M., Schwantes A., Sliva K., Sutter G., Schnierle B.S.
  Virus Res., 126, 1-8 (2007)
• Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with unfluenza virus H5N1. (pdf, 670 KB)
  Kreijtz J., Suezer Y., van Amerongen G., de Mutsert G., Schnierle B.S., Wood J., Kuiken T., Fouchier R., Löwer J., Osterhaus A., Sutter G., Rimmelzwaan G.
  J. Infect. Dis., 195, 1598-1606 (2007)
• Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV-1 infected individuals undergoing HAART. (online-abstract)
  Cosma A., Nagaraj R., Staib C., Diemer C., Wopfner F., Schätzl H., Busch D.H., Sutter G., Goebel F.D., Erfle V.
  AIDS Res. Hum. Retroviruses, 23, 782-793 (2007)
• Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. (online-abstract)
  Rollier C., Paranhos-Baccala G., Verschoor E.J., Verstrepen B.E., Drexhage J., Fagrouch Z., Berland J.-L., Komuran-Pradel F., Duverger B., Himoudi N., Staib C., Meyr M., Whelan M., Whelan J., Adams V., Larrea E., Riezu J.I., Bartosch B., Cosset F.-L., Spaan W.J.M., Diepolder H., Pape G., Sutter G., Inchauspe G., Heeney J.L.
  Hepatology, 45, 602-613 (2007)
• Therapeutic immunization with modified vaccinia virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy. (online-abstract)
  Überla K., Rosenwirth B., ten Haaft P., Heeney J.L., Sutter G., Erfle V.
  Med. Primatol., 36, 2-9 (2007)

nach oben2006

• T cell responses to respiratory syncytial virus fusion and attachmaent proteins in human peripheral bood mononuclear cells. (online-abstract)
  De Waal L., Suezer Y., Wyatt L.S., Sintnicolaas K., Sutter G., Moss B., Osterhaus A., De Swart R.L.
  Viral Immunol., 19, 669-678 (2006)
• Vaccinia virus replication is not affected by APOBEC3 family members. (pdf, 560 KB)
  Kremer M., Suezer Y., Martinez-Fernandez Y., Munk C., Sutter G., Schnierle B.S.
  Virol. J., 3, 86 (2006)
• Short-term but not post-exposure protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara. (pdf, 200 KB)
  Staib C., Suezer Y., Kisling S., Kalinke U., Sutter G.
  J. Gen. Virol., 87, 2917-2921 (2006)
• Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. (online-abstract)
  Kastenmüller W., Drexler I., Ludwig H., Erfle V., Peschel C., Bernhard H., Sutter G.
  Virology, 350, 276-288 (2006)
• Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus Ankara. (pdf, 410 KB)
  Ludwig H., Suezer Y., Waibler Z., Kalinke U., Schnierle B.S., Sutter G.
  J. Gen. Virol., 87, 1145-1155 (2006)
• A Toll-like receptor-independent antiviral response induced by double sranded B-form DNA. (online-abstract)
  Ishii K., Coban C., Kato H., Takahashi K., Torii Y., Takeshita F., Ludwig H., Sutter G., Suzuki K., Hemmi H., Sato S., Yamamoto M., Uematsu S., Kawai T., Takeuchi O., Akira S.
  Nat. Immunol., 7, 40-48 (2006)